Centene Corporation Sued for Securities Fraud

Strategic Insights -

Leading securities law firm Bleichmar Fonti & Auld LLP announced a lawsuit against Centene Corporation and its senior executives, alleging potential violations of the federal securities laws. Investors who purchased Centene securities may be eligible to join the case. Centene, a healthcare company providing services to consumers enrolled in government-sponsored healthcare programs, announced financial guidance for fiscal year 2025, which later turned out to be misleading. The company increased its 2025 guidance multiple times, despite experiencing lower-than-expected enrollment growth and increased morbidity rates. The stock price declined significantly after an independent actuarial report revealed the truth.

Key Takeaways:

  • A lawsuit has been filed against Centene Corporation and its senior executives for potential securities law violations.
  • Investors who purchased Centene securities may be eligible to join the case.
  • Centene announced financial guidance for fiscal year 2025, which turned out to be misleading.
  • The company increased its 2025 guidance multiple times, despite experiencing lower-than-expected enrollment growth and increased morbidity rates.
  • An independent actuarial report revealed the truth, leading to a significant decline in Centene's stock price.
  • Investors are encouraged to submit their information to Bleichmar Fonti & Auld LLP for potential legal options.
  • The law firm has a reputation for representing plaintiffs in securities class actions and shareholder litigation.
  • Bleichmar Fonti & Auld LLP has recovered significant amounts in shareholder litigation cases, including over $900 million from Tesla, Inc.'s Board of Directors and $420 million from Teva Pharmaceutical Ind. Ltd.

Statistics:

  • Centene's stock price fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025.
  • The majority of the markets that Centene serves were experiencing lower-than-expected enrollment growth and increased morbidity rates.
  • The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned: Lunstrum v. Centene Corporation, et al. , No. 25-cv-05659.

Sources:

  • Bleichmar Fonti & Auld LLP, press release (August 12, 2025)
  • Newsfile Corp., press release (August 12, 2025)
  • Chambers USA
  • The Legal 500
  • ISS SCAS
  • National Law Journal
  • Lawdragon
  • Law360
  • Thomson Reuters